Ribozyme begins Heptazyme HCV Phase II

RZYM began a U.S. Phase II trial in 70 patients of Heptazyme to treat chronic hepatitis C virus (HCV) infection. Patients will receive Heptazyme, a chemically synthesized ribozyme against HCV, alone o...